Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | SDHA | P31040 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822916 | 1.00 | F10 (0.40) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3523459 | 0.91 | L3MBTL1 (0.35) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3524012 | 0.91 | F10 (0.36) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3525596 | 0.90 | F10 (0.38) | F10ITGB3ITGA2BABCB11 | |
| SCHEMBL3525099 | 0.89 | GRM2 (0.37) | LMNAMEN1KMT2A | |
| SCHEMBL6823337 | 0.87 | PARP1 (0.35) | F10MAOB | |
| SCHEMBL3526042 | 0.87 | PARP1 (0.35) | F10MAOB | |
| SCHEMBL3522663 | 0.85 | TSHR (0.35) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3522293 | 0.83 | F10 (0.41) | F10MAOBMEN1KMT2A | |
| SCHEMBL3521790 | 0.83 | ALDH1A1 (0.35) | F10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | F10 4391/4885MAOA 2058/4885MAOB 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.